„The second objective is the development of sustainable vaccine production and supply solutions on the African continent. BioNTech is exploring possibilities to

„The second objective is the development of sustainable vaccine production and supply solutions on the African continent. BioNTech is exploring possibilities to set up state-of-the-art mRNA manufacturing facilities, either with partners or on its own. The facilities are expected to manufacture various mRNA-based vaccines upon approval to ensure sustainable supply operations.“, from the announcement They are planning to produce them there. From what I understand, mRNA vaccine production capabilities seem to be versatile. Swap out the mRNA payload and your facility can produce a whole different vaccine in no time. That would put the continent in a much better position if there is ever the need again to have a new vaccine rapidly produced.